ArticleEuropean journal of neurology2026
Associated Autoimmunity in Myasthenia Gravis in Denmark: A Nationwide Case-Control Study.
Article in European journal of neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Associated Autoimmunity in Myasthenia Gravis in Denmark: A Nationwide Case-Control Study.European journal of neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyasthenia gravis (MG) is an autoantibody-mediated neuromuscular disease often co-occurring with other autoimmune diseases (ADs). We aimed to determine the temporal relationship between other ADs and MG.
methodsWe conducted a nationwide, population-based case-control study of MG patients and 10 age-, sex-, and index date-matched controls from 1985 to 2020. We used conditional logistic regression to estimate odds ratios (ORs) for AD diagnoses preceding MG, and Cox regression to calculate hazard ratios (HRs) for ADs succeeding MG. Analyses were stratified by sex, age group (≤ 50 and > 50 years), baseline comorbidity, and time intervals (0-5 and 5-10 years) before and after MG.
resultsOur study population included 2110 MG cases (1060 females) and 21,100 matched controls, with 27.4% ≤ 50 years old. Before the index date, 5.2% of MG patients and 2.7% of controls were diagnosed with another AD, yielding an OR of 1.9 (95% CI 1.5-2.3). After MG diagnosis, 5.0% of MG patients and 2.7% of controls received an AD diagnosis (HR 2.1, 95% CI 1.2-2.6), with an overrepresentation of patients ≤ 50 years or younger, females, and patients with a low comorbidity level. Most diagnoses occurred within 5 years before MG onset. The strongest associations were observed for autoimmune thyroiditis, systemic lupus erythematosus, and pernicious anemia.
conclusionMG patients are twofold more likely to be diagnosed with another AD, especially MG patients ≤ 50 years and women, suggesting a shared autoimmune predisposition. Understanding the AD spectrum associated with MG could improve diagnostic accuracy and treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.